NeuroScientific Biopharmaceuticals Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NSB.AX | ENVB | QNTM | CRVO | CNSP | BIVI | |
|---|---|---|---|---|---|---|
| Market cap | 21.04M | 6.18M | 14.21M | 33.87M | 6.76M | 11.55M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -1.0 | -0.3 | -1.6 | -11.9 | -2.3 |
| Price/book | 1.4 | 0.7 | 2.1 | 1.3 | 0.4 | 1.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −60.00% | −81.30% | −83.54% | −68.09% | −44.61% | −29.63% |
| Today | +3.85% | −1.43% | −1.34% | −3.03% | −6.94% | +7.26% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All NSB.AX news ›Holobiome and Radicle Science launch large-scale gut-brain axis trial
The GUT-FEELINGS study is a two-year research initiative supported in part by the Advanced Research Projects Agency for Health (ARPA-H). It will test 19 food-derived prebiotic formulations against a placebo, with initial results expected…
NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle
Perth-based NeuroScientific Biopharmaceuticals has cleared a key regulatory hurdle for its planned phase two trial of its innovative StemSmart cell therapy in patients with treatment-resistant Crohn’s disease, with US regulators backing…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
smh.com.au1
-
thewest.com.au1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.